Incannex Healthcare Ltd ADR (IXHL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Incannex Healthcare Ltd ADR (IXHL) has a cash flow conversion efficiency ratio of -0.063x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.62 Million) by net assets ($73.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Incannex Healthcare Ltd ADR - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Incannex Healthcare Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Incannex Healthcare Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Incannex Healthcare Ltd ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AlphaTime Acquisition Corp Ordinary Shares
NASDAQ:ATMC
|
-0.001x |
|
S. Khonkaen Foods Public Company Limited
BK:SORKON
|
0.071x |
|
Ihuman Inc
NYSE:IH
|
0.193x |
|
Siyata Mobile Inc
NASDAQ:SYTA
|
-0.355x |
|
KebNi AB (publ)
ST:KEBNI-B
|
0.158x |
|
Aemulus Holdings Bhd
KLSE:0181
|
-0.202x |
|
Redwood Group Ltd
TWO:8426
|
-0.002x |
|
Bumi Teknokultura Unggul Tbk
JK:BTEK
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Incannex Healthcare Ltd ADR (2007–2025)
The table below shows the annual cash flow conversion efficiency of Incannex Healthcare Ltd ADR from 2007 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $13.39 Million | $-12.51 Million | -0.935x | +33.84% |
| 2024-06-30 | $11.22 Million | $-15.85 Million | -1.413x | -173.67% |
| 2023-06-30 | $20.82 Million | $-10.75 Million | -0.516x | -44.56% |
| 2022-06-30 | $24.76 Million | $-8.84 Million | -0.357x | +55.61% |
| 2021-06-30 | $6.44 Million | $-5.18 Million | -0.804x | +35.14% |
| 2020-06-30 | $2.17 Million | $-2.70 Million | -1.240x | -123.95% |
| 2019-06-30 | $-292.88K | $-1.52 Million | 5.179x | -30.37% |
| 2018-06-30 | $-283.71K | $-2.11 Million | 7.438x | -53.23% |
| 2017-06-30 | $-129.77K | $-2.06 Million | 15.904x | +1590.06% |
| 2016-06-30 | $-522.58K | $-491.77K | 0.941x | +134.95% |
| 2015-06-30 | $364.01K | $-980.28K | -2.693x | -1299.64% |
| 2014-06-30 | $1.64 Million | $367.56K | 0.224x | +163.32% |
| 2013-06-30 | $12.53 Million | $-4.44 Million | -0.355x | -6.14% |
| 2012-06-30 | $20.35 Million | $-6.79 Million | -0.334x | -71.39% |
| 2011-06-30 | $16.29 Million | $-3.18 Million | -0.195x | -37.01% |
| 2010-06-30 | $10.37 Million | $-1.47 Million | -0.142x | +80.41% |
| 2009-06-30 | $5.26 Million | $-3.82 Million | -0.726x | -520.88% |
| 2008-06-30 | $9.12 Million | $-1.07 Million | -0.117x | +37.52% |
| 2007-06-30 | $5.63 Million | $-1.05 Million | -0.187x | -- |
About Incannex Healthcare Ltd ADR
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synth… Read more